Dragon-Durey Marie-Agnès, Frémeaux-Bacchi Véronique, Loirat Chantal, Blouin Jacques, Niaudet Patrick, Deschenes Georges, Coppo Paul, Herman Fridman Wolf, Weiss Laurence
INSERM U430, Institut des Cordeliers, Paris, France.
J Am Soc Nephrol. 2004 Mar;15(3):787-95. doi: 10.1097/01.asn.0000115702.28859.a7.
Factor H (FH) is the major regulatory protein of the complement alternative pathway, with a structure consisting of a tandem array of 20 homologous units, called short consensus repeats (SCR). Reported are 16 FH-deficient patients. Among six patients with homozygous deficiency, four presented with membranoproliferative glomerulonephritis, and two with atypical hemolytic uremic syndrome (HUS). The ten other patients had heterozygous FH deficiency and developed atypical HUS. HUS onset occurred from birth to midadulthood, and disease progression was variable. Four children with homozygous or heterozygous FH deficiency and HUS underwent renal transplantation, which was successful in three but failed as a result of recurrence of HUS in one patient. All but one patient exhibited alternative pathway-mediated complement consumption, with no detectable FH antigenic levels or with 50% immunochemical or functional FH levels in the case of complete or partial deficiency, respectively. The molecular mechanisms of the deficiency were documented in all cases by exon-specific sequencing analysis. These mechanisms included nucleotide substitutions, insertion, or deletion located in SCR 2, 7, 11, 13, 15, and 20, leading to an amino acid substitution or to a stop codon. This report emphasizes the variability in the clinical progression of kidney diseases associated with FH deficiencies. Genetic analysis reveals the molecular abnormalities associated with FH deficiencies to be polymorphous.
补体H因子(FH)是补体替代途径的主要调节蛋白,其结构由20个同源单位的串联阵列组成,称为短共识重复序列(SCR)。报告了16例FH缺陷患者。在6例纯合缺陷患者中,4例表现为膜增生性肾小球肾炎,2例表现为非典型溶血尿毒症综合征(HUS)。其他10例患者为杂合性FH缺陷,并发生了非典型HUS。HUS发病从出生至成年中期,疾病进展各不相同。4例患有纯合或杂合FH缺陷及HUS的儿童接受了肾移植,其中3例成功,但1例因HUS复发而失败。除1例患者外,所有患者均表现出替代途径介导的补体消耗,在完全或部分缺陷的情况下,分别检测不到FH抗原水平或免疫化学或功能FH水平为50%。所有病例均通过外显子特异性测序分析记录了缺陷的分子机制。这些机制包括位于SCR 2、7、11、13、15和20中的核苷酸替换、插入或缺失,导致氨基酸替换或终止密码子。本报告强调了与FH缺陷相关的肾脏疾病临床进展的变异性。基因分析显示与FH缺陷相关的分子异常具有多态性。